In this handout photo released by the University of Oxford a doctor takes blood samples for use in a coronavirus vaccine trial in Oxford, England on Thursday June 25, 2020. Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. In research published Monday July 20, 2020 in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55. (John Cairns, University of Oxford via AP)
By Maria Cheng
Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot.
British researchers first began testing the vaccine in April in about 1,000 people, half of whom got the experimental vaccine. Such early trials are usually designed only to evaluate safety, but in this case experts were also looking to see what kind of immune response was provoked.
In research published Monday in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55.
“We are seeing good immune response in almost everybody,” said Dr. Adrian Hill, director of the Jenner Institute at Oxford University. “What this vaccine does particularly well is trigger both arms of the immune system,” he said.
Hill said that neutralizing antibodies are produced — molecules which are key to blocking infection. In addition, the vaccine also causes a reaction in the body's T-cells which help to fight off the coronavirus.
He said that larger trials evaluating the vaccine's effectiveness, involving about 10,000 people in the U.K. as well as participants in South Africa and Brazil are still underway. Another big trial is slated to start in the U.S. soon, aiming to enroll about 30,000 people.
How quickly scientists are able to determine the vaccine's effectiveness will depend largely on how much more transmission there is, but Hill estimated they might have sufficient data by the end of the year to decide if the vaccine should be adopted for mass vaccination campaigns.
He said the vaccine seemed to produce a comparable level of antibodies to those produced by people who recovered from a COVID-19 infection and hoped that the T-cell response would provide extra protection.
“There's increasing evidence that having a T-cell response as well as antibodies could be very important in controlling COVID-19,” Hill said. He suggested the immune response might be boosted after a second dose; their trial tested two doses administered about four weeks apart.
Hill said Oxford's vaccine is designed to reduce disease and transmission. It uses a harmless virus — a chimpanzee cold virus, engineered so it can’t spread — to carry the coronavirus’ spike protein into the body, which should trigger an immune system response.
Hill said Oxford has partnered with drugmaker AstraZeneca to produce their vaccine globally, and that the company has already committed to making 2 billion doses.
“Even 2 billion doses may not be enough,” he said, underlining the importance of having multiple shots to combat the coronavirus.
“There was a hope that if we had a vaccine quickly enough, we could put out the pandemic,” Hill said, noting the continuing surge of infections globally. “I think it's going to be very difficult to control this pandemic without a vaccine.”
Numerous countries including Germany, France, the Netherlands, Italy, U.S. and the U.K. have all signed deals to receive hundreds of millions of doses of the vaccine — which has not yet been licensed — with the first deliveries scheduled for the fall. British politicians have promised that if the shot proves effective, Britons will be the first to get it.
Last week, American researchers announced that the first COVID-19 vaccine tested there boosted people’s immune systems just as scientists had hoped and the shots will now enter the final phase of testing. That vaccine, developed by the National Institutes of Health and Moderna, produced the molecules key to blocking infection in volunteers who got it, at levels comparable to people who survived a COVID-19 infection.
About a dozen different experimental vaccines are in early stages of human testing or poised to start, mostly in China, the U.S. and Europe, with dozens more in earlier stages of development.
British officials said Monday they had also signed a deal to buy 90 million doses of experimental COVID-19 vaccines being developed by the pharmaceutical giant Pfizer and others.
In a statement, the British government said it had secured access to a vaccine candidate being developed by Pfizer and BioNTech, in addition to another experimental vaccine researched by Valneva.
After two decades of engineering, over $10 billion, and a series of delays, the most powerful telescope built by NASA is finally scheduled to launch on Saturday. The James Webb Space Telescope was built to provide a fresh look at the universe by detecting light that is invisible to the human eye and to reveal new information about the universe's oldest stars and galaxies. Lou Strolger, observatory scientist and deputy head of instruments division, space telescope, joins Cheddar News.
Carlo and Baker kick off the weirdest week of the year with all the news you missed over the holiday weekend, including calls for the CDC to shorten its isolation window as Omicron sweeps through the country.
The 2022 Winter Olympics will be without some of hockey's biggest players. The NHL and the NHL Player's Association have agreed to not participate in the men's hockey tournament at the Games in Beijing next year. The league has been forced to postpone some games because of a rise in COVID-19 cases among players. Washington Post sports reporter Samantha Pell joins Cheddar News' Closing Bell to discuss what this could mean for the Winter Olympics and the sport of hockey.
The National Highway Traffic Safety Administration has opened a formal investigation into Tesla. The agency is looking into about 580,000 Tesla vehicles, and a feature called 'Passenger Play' which allows drivers to play video games on the center touch screen. The feature previously only worked when a vehicle was in park; but, the NHTSA says it has confirmed that the feature has been available while vehicles are in motion since December of 2020. iSeeCars.com executive analyst Karl Brauer joins Cheddar News' Closing Bell to discuss.
Baron Davis and Kate Hudson want you to bring cannabis home for the holidays. The cannabis-infused seltzer brand Cann released a new spot featuring the actress and former NBA player. The campaign comes hand in hand with Cann's launch of a new holiday bundle, which includes its product with Hudson's King Street Vodka. Davis and Hudson are also Cann investors. Cheddar cannabis reporter Chloe Aiello spoke to Davis about his involvement with the company and its new campaign.
Healthcare workforce management platform ShiftMed
recently announced a $45 million funding round.
The company's platform connects nurses and healthcare professionals to hospitals and other healthcare providers.
ShiftMed's new funding comes amid widespread labor shortages in the healthcare sector. The company's CEO Todd Walrath joins Cheddar News' Closing Bell to discuss.
Universities like UCLA, Yale, and Duke have announced they're implementing remote learning amid the COVID omicron variant surge, despite President Biden recommending that K-12 schools should continue in-person education. Jared C. Bass, senior director for Higher Education at American Progress, joined Cheddar to break down what institutions of higher education might be considering differently. "I think some universities are allowing periods of a bit of a respite to allow students to get testing and make sure when they do return back to campus that they're healthy," he noted.
Supply chain issues have become one of the biggest roadblocks for the U.S. EV market, with production woes likely to stunt the industry's growth in 2022. Rich Steinberg, electric vehicle expert and industry advisor, told Cheddar that the Biden administration investing in domestic mining for essential minerals used in battery manufacturing — such as lithium — could help alleviate the bottlenecks. "Some of those same materials are available domestically, they just haven't been prioritized," he said, noting the paradox between green tech and "dirty" mining. "The good news is that there are ways to extract those materials cleanly."
Hyperfine, the pioneer of the very first FDA-approved portable MRI device, made its public debut on the Nasdaq via a SPAC merger. CEO Dave Scott joined Cheddar's "Opening Bell" to discuss the IPO launch, the company's valuation at $580 million, and the impact of its machine called Swoop. "We can roll an MRI system, our MRI Swoop system, right into the room where you are, right up to your patient bedside, and scan you right there and get an image in less than an hour," he explained.
Dr. Rob Davidson, Executive Director of the Committee to Protect Health Care and an ER Physician in West Michigan, joins Cheddar News to break down the expectations of Pfizer's new COVID-19 treatment pill.
